Hologic (WBO:HOLX) Common Stock : €3 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Hologic Common Stock?

Hologic's quarterly common stock increased from Jun. 2023 (€3 Mil) to Sep. 2023 (€3 Mil) but then declined from Sep. 2023 (€3 Mil) to Dec. 2023 (€3 Mil).

Hologic's annual common stock increased from Sep. 2021 (€3 Mil) to Sep. 2022 (€3 Mil) but then declined from Sep. 2022 (€3 Mil) to Sep. 2023 (€3 Mil).

Hologic Common Stock Historical Data

The historical data trend for Hologic's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Common Stock Chart

Hologic Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Common Stock

Get a 7-Day Free Trial

2.63

2.46

2.55

3.03

2.81

Hologic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															2.83	2.80	2.77	2.81	2.75

Hologic Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Hologic (WBO:HOLX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (WBO:HOLX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

HOLX:USA HOLX:Mexico HO1:Germany

Address

250 Campus Drive, Marlborough, MA, USA, 01752

Website

http://www.hologic.com

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.